Yes-associated protein (YAP), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene located at chromosome 11q22. Since we previously reported amplification of 11q22 region in esophageal squamous cell carcinoma (ESCC), in this study we focused on the clinical significance and biological functions of YAP in this tumor. Frequent overexpression of YAP protein was observed in ESCC cells including those with a robust amplicon at position 11q22. Overexpression of the YAP protein was frequently detected in primary tumors of ESCC as well. Patients with YAP-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors, and YAP positivity was independently associated with a worse outcome in the multivariate analysis. Further analyses in cells in which YAP was either overexpressed or depleted confirmed that cell proliferation was promoted in a YAP isoform-independent but YAP expression level-dependent manner. YAP depletion inhibited cell proliferation mainly in the G 0 -G 1 phase and induced an increase in CDKN1A/p21 transcription but a decrease in BIRC5/survivin transcription. Our results indicate that YAP is a putative oncogene in ESCC and it represents a potential diagnostic and therapeutic target.
Introduction
The Hippo signaling pathway regulates the balance between cell proliferation and apoptosis (1) . Yes-associated protein (YAP) is the mammalian ortholog of Drosophila Yorkie (yki), which is a negatively regulated effector of the Hippo pathway and functions as a transcriptional coactivator or corepressor in the regulation of cell growth, proliferation and apoptosis (2) . Given the essential role of YAP in cellular growth, knockout of the YAP gene in mice leads to early embryonic death (3) . YAP was described to increase the ability of p73 to induce apoptosis as a consequence of DNA damage and be important for c-Jun-dependent apoptosis, suggesting that, under certain conditions of stress, YAP acts as a tumor suppressor (4) (5) (6) (7) (8) (9) . However, a majority of recent studies document YAP as a bona fide oncogene: YAP amplification and overexpression were observed in various human cancers and mouse models of cancer (10) (11) (12) (13) (14) (15) (16) ; overexpression of YAP in nontransformed mammary epithelial cells induced epithelial-mesenchymal transition, suppression of apoptosis, growth factor-independent proliferation and anchorage-independent growth (11); YAP cooperated with myc oncogene to stimulate tumor growth in nude mice (12) and transgenic mice with liver-targeted YAP overexpression showed a dramatic increase in liver size that eventually resulted in hepatic tumors (17, 18) . Considering those findings, YAP may have a dual role in signaling, which depends on context, stress and/or cell lineage because it is placed at the crossroad of many signaling pathways (19) . In the current study, we focused on the role of YAP gene in a cancer that is prevalent in our country.
Esophageal carcinoma is the sixth most frequent cause of cancerrelated death worldwide (20) , and esophageal squamous cell carcinoma (ESCC) accounts for $90% of esophageal carcinomas diagnosed in Asian countries including Japan. Although accumulated evidence suggests that multiple genetic alterations occurring sequentially in a cell lineage underlie the carcinogenesis of ESCC, the repertoire of genetic alterations identified so far in ESCC cannot fully account for the pathogenesis. Among the genetic alterations detected in cancer, the amplification of chromosomal DNA is one of the mechanisms capable of activating genes whose overexpression contributes to the development and progression of human cancer, including ESCC (21) . As such, the amplification event points to candidate tumor-promoting genes.
Before the YAP gene was mapped precisely in the human genome, in ESCC cell lines, we detected amplification at 11q22, which contains YAP gene and we also identified cellular inhibitor of apoptosis 1 (cIAP1, BIRC2) within the amplicon as a possible tumor-promoting gene (22) . Since YAP is located $100 kb centromeric to cIAP1/BIRC2 according to the human genome database (http://www.ncbi.nlm.nih.-gov) and seems to be amplified with cIAP1 within the 11q amplicon in ESCC (22) , YAP in concert with cIAP1 could contribute to the neoplastic phenotype of ESCC. In the non-neoplastic esophageal mucosa, YAP immunoreactivity, especially in the nucleus, was shown to be positive in the proliferating basal layer of the epithelium but negative in the terminally differentiated mature squamous epithelium toward the surface (10) . These are novel observations as, to our knowledge, the expression status and functional significance of YAP in the tumorigenesis of ESCC have not been previously characterized.
Here, we demonstrate that four isoforms of YAP, including one newly identified isoform, were frequently overexpressed in ESCC. We also showed that patients with YAP-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors. We also report proliferation-promoting activity of YAP, at least in part, through the inhibition of CDKN1A/p21 transcription and induction of BIRC5/survivin transcription, either directly or indirectly. Interestingly, the YAP activity was isoform independent. These finding suggest YAP to be a potential target in the treatment of ESCC. from patients. None of these patients underwent endoscopic mucosal resection, palliative resection, preoperative chemotherapy or radiotherapy, and none had synchronous or metachronous multiple cancers in other organs. Disease stage was defined in accordance with the International Union against Cancer and following the tumor-lymph node-metastases classification. In this series, all the M1 tumors had distant lymph node metastases and there was no organ metastasis. The median follow-up period for the surviving patients was 19 (ranging from 1 to 103) months.
Western blotting
The anti-YAP (H-125), anti-cIAP1 (H-83), anti-p21 (C-19), anti-survivin (D-8) and Lamin B (C-20) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); anti-b-actin antibody from Sigma (St Louis, MO); antiKi67 antibody from DAKO (Carpinteria, CA) and anti-phospho-YAP (Ser127) and anti-b-tubulin antibodies from Cell Signaling Technology (Danvers, MA). Cells were lysed in Tris buffer (50 mM, pH 7.5) containing 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.5% NP-40, 10% glycerol, 100 mM NaF, 10 mM sodium pyrophosphate, 2 mM Na 2 VO 3 and a protease inhibitor cocktail (Roche, Tokyo, Japan), and lysates were analyzed as described elsewhere (23) . Nuclear and cytoplasmic proteins were extracted from cells separately using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL).
Immunofluorescence microscopy Cells were fixed in 10% trichloroacetic acid, permeabilized with 0.2% Triton X-100 and treated with blocking solution (1% bovine serum albumin, in phosphate-buffered saline) and then incubated with the primary antibodies (YAP, 1:100 and/or Ki67, 1:200) for 1 h. The bound antibody was visualized using a fluorescein isothiocyanate-conjugated or Cy3-conjugated secondary antibody (1:1000). After being mounted with 4#,6#-diamidino-2-phenylindole to stain nuclei, the cells were observed under a fluorescence microscope (BZ-8100; Keyence, Osaka, Japan).
Immunohistochemistry
Tumor samples were fixed with 10% formaldehyde in phosphate-buffered saline, embedded in paraffin, sectioned into 4 lm thick slices and subjected to immunohistochemical staining of YAP protein with the avidin-biotin-peroxidase method (24) . In brief, endogenous peroxidases were quenched by incubating the sections for 20 min in 3% H 2 O 2 . Antigen retrieval was performed by heating the samples in 10 mM citrate buffer (pH 6.0) at 120°C for 15 min using an autoclave. After treatment with Block Ace (Dainippon Sumitomo Pharmaceutical, Osaka, Japan) for 30 min at room temperature, the sections were incubated at 4°C overnight with an anti-YAP (1:100) antibody. The avidin-biotin-peroxidase complex system (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) was used for color development with diaminobenzidine tetrahydrochloride. The slides were counterstained with Mayer's hematoxylin. A formalin-fixed ESCC cell line overexpressing YAP (KYSE170) was used as a positive control, whereas a formalin-fixed ESCC cell line with low expression of YAP (KYSE1240) was included as a negative control. The percentage of the total cell population that expressed YAP was evaluated for each case at Â200 magnification. Expression of YAP protein was graded as either positive (!30% of the nucleus or cytoplasm showing immunopositivity; cytoplasmic or nuclear positive, respectively) or negative (,30% of the nucleus or cytoplasm showing immunopositivity or no staining; cytoplasmic or nuclear negative, respectively).
Reverse transcription-polymerase chain reaction Single-stranded complementary DNA was generated from total RNA. The messenger RNA (mRNA) expression pattern was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) using gene-specific primer sets (supplementary Table S3 is available at Carcinogenesis Online). PCR products were electrophoresed in 3% agarose gels, and bands were quantified using LAS-3000 (Fujifilm, Tokyo, Japan) and Multi Gauge software (Fujifilm). Levels of mRNA expression were measured with a quantitative real-time fluorescence detection method (ABI PRISM 7500 sequence detection System; Applied Biosystems, Foster City, CA) using TaqMan Gene Expression Assays (Hs00193201_m1 and Hs00231069_m1 for CDKN1A/p21 and BIRC5/survivin, respectively; Applied Biosystems) according to the manufacturer's instructions. Gene expression values are expressed as ratios between the genes of interest and an internal reference gene (Hs99999903_m1 for beta-actin, ACTB; Applied Biosystems) that provides a normalization factor for the amount of RNA isolated from a specimen and subsequently normalized with the value in the controls (relative expression level). Each assay was performed in duplicate for each sample.
Expression constructs and colony formation assay
Plasmids expressing each of the YAP isoforms (pcDNA3.1-YAP-a, -b, -c and -d) were obtained by cloning the full coding sequences for wild-type YAP-a, -b, -c and -d, respectively, into the vector pcDNA3.1(À) (Invitrogen, St Louis, MO). pcDNA3.1-YAP-a, -b, -c or -d or the empty vector (pcDNA3.1-mock), as a control, was introduced into ESCC cells as described previously (23) . The expression of YAP protein in transfected cells was confirmed by western blotting. After 3 weeks of incubation with appropriate concentrations of G418, cells were fixed and stained with crystal violet.
Loss-of-function by small interfering RNA and cell growth analysis Loss-of-function screening was done using small interfering RNAs (siRNAs) purchased from Invitrogen targeting the YAP gene (HSS115942, HSS115943 or HSS115944) or the cIAP1 gene (HSS100559) and a universal negative control . Each siRNA (total 20 nM) was transfected into ESCC cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The knockdown of a target gene was confirmed by quantitative real-time RT-PCR and western blotting. The numbers of viable cells at various time points after transfection were assessed by a colorimetric water-soluble tetrazolium salt assay as described elsewhere (23) . The cell cycle was evaluated 72 h after transfection by fluorescence-activated cell sorting as described elsewhere (23) .
Statistical analysis
The clinicopathological variables pertaining to the corresponding patients were analyzed for statistical significance by the v 2 or Fisher's exact test. For the analysis of survival, Kaplan-Meier survival curves were constructed for groups based on univariate predictors and differences between the groups were tested with the log-rank test. Univariate and multivariate survival analyses were performed using the likelihood ratio test of the stratified Cox proportional hazards model. Differences between subgroups were tested with the Student's t-test. For multiple group comparisons, a one-way analysis of variance, followed by Scheffé's post-hoc test, was used. Differences were assessed with a two-sided test and considered significant at the P , 0.05 level.
Results

YAP protein is frequently overexpressed in human ESCC
To determine whether YAP may be involved in human ESCC, we first performed protein expression analyses in a panel of cell lines of ESCC using an antibody raised against 125 amino acid long, C-terminal fragment of YAP. We observed frequent high expression of the YAP protein in ESCC cell lines ( Figure 1A ) including those with high-copy amplification at 11q22 (KYSE170 and KYSE2270) (22) . At least two bands (arrowheads in Figure 1A ) at $75 kD (major) and 65 kD (minor) were detected. Since YAP protein were overexpressed in cells with remarkable amplification of this gene (22) as well as in cells without amplification ( Figure 1A ), YAP amplification seems to be only part of the mechanism to induce its overexpression/activation. The YAP protein was predominantly located in the cytoplasm of ESCC cells with the 11q22 amplification ( Figure 1B and C).
Immunohistochemical analysis ( Figure 1D -J) revealed that YAP protein is frequently overexpressed in primary tumors of ESCC compared with nontumorous esophageal epithelia in either the cytoplasm or nucleus. In 120 primary ESCC tumors, positive nuclear and cytoplasmic YAP immunoreactivity was detected in 69 (57.5%) and 74 (61.7%) cases, respectively (supplementary Tables S1 and S2 are available at Carcinogenesis Online). Notably, basal cell layer cells of nontumorous epithelia also clearly expressed YAP protein, predominantly in the nucleus ( Figure 1F ).
Nuclear YAP protein overexpression associated with short overall survival We examined the clinicopathological significance of the nuclear or cytoplasmic overexpression of YAP in 120 primary ESCC tumors based on the immunohistochemical staining pattern of this protein (supplementary Tables S1 and S2 are available at Carcinogenesis Online). No significant association between any clinicopathological characteristics and nuclear or cytoplasmic YAP immunoreactivity was observed in our set of primary tumors. However, Kaplan-Meier survival estimates ( Figure 1K ) showed that nuclear immunoreactivity of YAP in tumor cells was significantly associated with a worse overall survival in all cases (P 5 0.0213, log-rank test). In the Cox proportional hazard regression model (Table I) , univariate analyses demonstrated that YAP protein expression, gender and pN category and stage T. Muramatsu et al. in the tumor-lymph node-metastases classification were significantly associated with overall survival. In the multivariate analysis using a stepwise Cox regression procedure, nuclear YAP expression status, gender and tumor stage according to the tumor-lymph node-metastases classification were identified as independently selected predictive factors for overall survival in both forward and backward procedures (K) Kaplan-Meier curves for overall survival rates of patients with primary ESCC at all stages according to the nuclear expression of YAP. Nuclear YAP immunoreactivity of tumor cells was significantly associated with a worse overall survival at all stages (P 5 0.0213, log-rank test).
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(P 5 0.0420, 0.0452 and 0.002, respectively). In contrast to the nuclear YAP immunoreactivity association with survival, no significant association was observed between cytoplasmic immunoreactivity of YAP in tumor cells and overall survival (supplementary Figure S1 is available at Carcinogenesis Online).
These observations are consistent with the prevailing notion that proliferative or oncogenic signaling of the Hippo pathway requires nuclear localization of YAP (18) .
Four major isoforms of YAP include two novel types
Since several forms of YAP protein were observed in ESCC cells ( Figure 1A and data not shown) and some isoforms of human YAP were previously reported (24, 25) , we decided to clone the full-length coding sequence for each of the YAP isoforms using RT-PCR. Consequently, we identified four variants (Figure 2A Figure 2B ). To determine the relative transcription levels of the four YAP isoforms, we designed primer sets ( Figure 2B ; supplementary Table S3 is available at Carcinogenesis Online) for RT-PCR. All four isoforms were detectable in normal esophagus and the ESCC cell line with the 11q22 amplification (KYSE170), although YAP-c was predominantly expressed in the normal esophagus, whereas YAP-d was predominantly expressed in KYSE170 cells ( Figure 2C ). The mRNA expression pattern of the four isoforms of YAP was similar among all ESCC cell lines examined regardless of the 11q22 amplification ( Figure 2D ). Since we did not detect smaller protein products of previously identified two putative, short isoforms of human YAP (GenBank accession number, BAG62143 and BAG65295), which miss in part, or completely, the WW domain region, in ESCC cell lines and tissues (data not shown), we did not follow the analysis of these two isoforms extensively.
Proliferation-promoting effect of YAP overexpression in ESCC cells
Increased expression was observed for all four major isoforms in ESCC cell lines, and the pattern of distribution was similar among cell lines examined, making it unclear whether all the YAP isoforms or some specific isoforms play a role in the tumorigenesis of ESCC through overexpression. To assess the effects of YAP on cell proliferation especially in ESCC cells, we conducted colony formation assays using expression construct encoding full-length sequence of each YAP isoform in an ESCC cell line with relatively low endogenous expression of this gene (KYSE1240; Figures 1A and 2D ). Transient transfection of the expression construct for each isoform produced the corresponding protein, which localized predominantly in the cytoplasm, and faint band of endogenous YAP expression was also observed ( Figure 3A and B) . YAP-expressing constructs produced consistently more colonies than did the empty plasmid, regardless of the isoform ( Figure 3C ). In addition, no difference was observed in the occupancy of the stained area among the YAP isoforms ( Figure 3D ), suggesting that each isoform promotes cell proliferation in ESCC cells independently of the number of WW domains and the existence of short insert sequences.
Suppression of cell growth by downregulation of YAP expression in ESCC cells
We next performed a cell growth assay using YAP-specific siRNA to investigate whether the knockdown of YAP expression would suppress the proliferation of KYSE170 cells showing amplification/overexpression of YAP. Since each YAP isoform seems to show similar growth-promoting activity in ESCC cells, we used YAP-specific siRNA, which can knockdown all isoforms of YAP. In KYSE170 cells, the expression of all the isoforms was efficiently knocked down 24-72 h after the transient introduction of YAP-specific siRNAs (siRNA-YAP#1, #2 and #3) compared with a negative control siRNA (siRNA-NC, Figure 4A ). The proliferation of KYSE170 cells was decreased after the knockdown of endogenous YAP expression compared with the control (Figure 4B ). On the other hand, knockdown of YAP had a minimal effect on proliferation in KYSE1240 cells expressing relatively low levels of this gene (Figure 4Aand B) , suggesting that the growth-promoting effect of YAP in ESCC cells depends on its expression level. In order to unequivocally confirm the specificity of siRNA for YAP and assess the difference in the growthpromoting effect of each YAP isoform, we performed YAP-siRNA rescue experiments using cells with siRNA-induced YAP-depletion (supplementary Figure S2 is available at Carcinogenesis Online). We stably introduced individual expression constructs producing each of the four isoforms of YAP, which are refractory to siRNA-YAP#2, into KYSE170 cells and then depleted the endogenous YAP by transiently introducing siRNA-YAP#2. The expression of each YAP isoform was detected, and each isoform partially restored YAP depletion inhibited cell proliferation possibly due to lower expression level of each isoform in stable transfectants compared with their parental cells. However, no significant differences were observed among YAP isoforms. This result is consistent with that observed in colony formation assays using transiently introduced constructs producing each YAP isoform.
Since our previous studies and the current study demonstrated that YAP and cIAP1, two possible oncogenes located at 11q22, were cooverexpressed in some of the ESCC cell lines, including KYSE170 and KYSE2270 having the 11q22 amplification, we tested whether the two genes could cooperate to promote the proliferation of ESCC cells. We accomplished that test by using a double-knockdown with siRNA specific for each gene (supplementary Figure S3 is available at Carcinogenesis Online). In KYSE170 cells, the transient introduction of 10 nM of YAP-or cIAP1-specific siRNA alone with 10 nM of an siRNA-NC inhibited cell proliferation compared with that of 20 nM of siRNA-NC. In addition, the introduction of both YAP-and cIAP1-specific siRNAs (10 nM each) induced a larger decrease in cell proliferation compared with that of each siRNA (10 nM with 10 nM of a siRNA-NC), suggesting YAP and cIAP1 cooperatively promote tumorigenesis in ESCC.
Mechanisms of YAP-induced growth-promoting activity in ESCC cells
To gain further insight into the potential mechanism of YAP as an oncogene in esophageal carcinogenesis, we performed fluorescence-activated cell sorting, fluorescence immunocytochemical and expression analyses in ESCC cells treated with YAP-specific siRNA. Consistent with the results of the cell proliferation experiment, siRNA-YAP treatment resulted in an accumulation of cells in the G 0 -G 1 phase compared with siRNA-NC-treated counterparts in the KYSE170 cell line in a fluorescence-activated cell sorting analysis, whereas a minimal effect was observed in siRNA-YAP-treated KYSE1240 cells ( Figure  4C ). In addition, we stained siRNA-YAP-treated KYSE170 cells with anti-YAP antibody and a cell proliferation marker, anti-Ki67 antibody, and found that Ki67 expression status was clearly correlated with YAP expression status: cells which retained the expression of YAP were positive for Ki67, whereas cells in which YAP was effectively knocked down tested negative ( Figure 4D ). Since CDKN1A/p21 
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and BIRC5/survivin were reported as possible cell cycle-associated targets for transcriptional suppression and activation by YAP, respectively (13, (26) (27) (28) , we investigated CDKN1A/p21 and BIRC5/survivin expression after treatment with siRNA for YAP. After the downregulation of YAP expression, CDKN1A/p21 and BIRC5/survivin expression was remarkably induced and suppressed, respectively, at both the mRNA and protein levels in KYSE170 cells ( Figure 5A and B) but only slightly affected in KYSE1240 cells (supplementary Figure S4 is available at Carcinogenesis Online). The results confirm YAP to induce and reduce transcription of CDKN1A/p21 and BIRC5/survivin in a YAP expression level-dependent manner, resulting in G 0 -G 1 arrest, although it remains unclear whether these are direct or indirect effects of YAP.
Discussion
The Hippo signaling pathway is gaining recognition as an important player in both organ size control and tumorigenesis, which are physiological and pathological processes that share common cellular signaling mechanisms (29) . Since the disruption of any factor in this pathway can lead to tumorigenesis, it is not surprising that YAP functions as an oncogene and the major downstream effector of the Hippo pathway. As it is the case for ESCC, the YAP locus is also amplified in other human cancers, including intracranial ependymomas, oral squamous cell carcinomas and medulloblastomas (16, (30) (31) (32) . Two reports identified YAP as a driving oncogene of the 11q22 amplicon in human hepatocellular carcinoma (HCC) and breast cancer (11, 12) . Elevated The stained area was calculated by densitometry using an image analyzer (LAS3000; Fujifilm) and Black area calculation STD software (Gougasha, Kyoto, Japan). Columns, means of three separate experiments, each performed in triplicate; bars, standard deviation (histogram). Differences among multiple comparisons were analyzed by one-way analysis of variance with subsequent Scheffé's tests: asterisks represents P , 0.05 versus empty vector (Mock).
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YAP expression and nuclear localization have been observed in multiple types of cancer, including HCC, colon cancer, ovarian cancer, lung cancer and prostate cancer (12, 13, 14, 18, 33, 34) . Only for HCC patients, however, YAP was determined to be an independent prognostic marker for overall survival and disease-free survival (33) . In this study, we demonstrated that overexpression and nuclear localization of YAP in ESCC tissues was associated with a poor prognosis for patients with this disease. In addition, we revealed that YAP's overexpression in ESCC cells promoted cell proliferation, whereas its depletion impaired cell viability through the transcriptional regulation of putative target genes. At present, the available data are still fragmentary and insufficient to delineate the tissue specificity and frequency of mutations/alterations affecting the components of the Hippo pathway, including YAP, in human cancers. A previous report (33) and the present study indicate that dysregulation of YAP plays a role in tumorigenesis and may be useful as an independent prognostic marker, at least in HCC and ESCC. Although it remains unclear whether this is due to a tissue-specific function of the Hippo pathway or simply due to a lack of studies of this pathway in other tissues.
In this study, we identified two novel isoforms of YAP, which have not been described in previous reports, although no functional differences was found among the YAP isoforms in cell growth-promoting activity assay. YAP has an N-terminal proline-rich domain, a TEADbinding region, one (YAP-a and -b) or two (YAP-c and -d) WW domains, a Src homology domain 3-(SH3-) binding motif, an insertion sequence of unknown function (YAP-b and -d), a coiled-coil domain, a transcription activation domain and a C-terminal PDZ-binding motif. Our results suggest that neither the number of WW domains nor the uncharacterized insertion sequence affects the growth-promoting activity of the YAP protein. Although it is still not clear how cells use the YAP isoforms differently (35) , normal esophagus and ESCC cells predominantly express YAP-c and -d unrelated to the YAP level. Among these two isoforms, interestingly, the normal esophagus mainly expresses YAP-c, whereas ESCC cells mostly express YAP-d. Therefore, it is possible that unknown functions of YAP other than in cell proliferation, which differ among the isoforms, are differentially used in a tissueand/or context-specific manner through transcriptional regulation.
Knockdown of the overexpressed YAP inhibits the proliferation of ESCC cells mainly by inducing G 0 -G 1 arrest, not by inducing apoptosis, in an expression-dependent manner, suggesting that ESCC cells overexpressing YAP follow a highly activated YAP-mediated pathway of proliferation. Since CDKN1A/p21 transcription was induced by YAP's knockdown and YAP is a transcription cofactor, which itself has no DNA-binding activity, YAP may directly inhibit CDKN1A/ p21 transcription as a transcription corepressor regulating specific transcription factors and resulting in the promotion of cell proliferation ( Figure 5C ). One candidate for such transcription factors is RUNX2, which was reported recently (27) . In a preliminary experiment using a nuclear extract from KYSE170 cells, indeed, endogenous RUNX2 was co-immunoprecipitated with YAP (supplementary Figure S5 is available at Carcinogenesis Online). However, it is unclear whether RUNX2 is a critical transcription factor for YAP-induced CDKN1A/ p21 suppression in the esophagus because the expression level of RUNX2 is relatively low in the esophagus and Vitolo et al. (27) showed that YAP overexpression promoted cell proliferation but prevented RUNX2-mediated repression of CDKN1A/p21 transcription. TEAD family (TEAD1-4), four highly homologous proteins sharing a conserved DNA-binding TEA domain in humans, has been demonstrated to be important for the growth-promoting function of YAP (2, 36) . Knockdown of TEAD aborts expression of the majority of YAP-inducible genes and largely attenuates YAP-induced overgrowth, epithelial-mesenchymal transition and oncogenic transformation (2) . Furthermore, the phenotype of TEAD1/TEAD2 double-knockout mice resembles that of YAP-knockout mice (37) , suggesting the TEAD proteins to be a key downstream transcription factors mediating YAP's cellular function. However, in Drosophila, yki mutant cells have more severe growth defects than scalloped, a Drosophila TEAD homolog, mutant cells (38) and overexpression of the scalloped-binding-defective Yki-S97A elicits a reduced but still obvious overgrowth in Drosophila eyes and wings (2) . Consistently, the TEAD-binding-defective YAP-S94A mutant can still induce an expression of a fraction of YAP-regulated genes (2), indicating that besides TEAD, additional transcription factors may be used by YAP/yki to stimulate cell and tissue growth. Since all four functionally redundant members of the TEAD family are ubiquitously expressed in ESCC cells (data not shown), it is difficult to knockdown all TEAD proteins to assess whether the inactivation of TEAD can abort expression of the majority of YAP-inducible genes and largely attenuate YAP-induced growth promotion in ESCC cells. Further analysis will be needed to screen all possible transcription factors, which activate or repress transcription of target genes, working with YAP in ESCC cells. Dong et al. (13) used a microarray to identify YAP-induced gene expression in murine livers and demonstrated that YAP induced the transcription of many genes, which are normally associated with hepatocyte proliferation, such as Ki67, c-myc, SOX4, H19 and AFP, and several negative regulators of apoptosis, such as the IAP family members BIRC5/survivin and BIRC2/cIAP1. Our expression analyses using real-time RT-PCR in ESCC cells with the amplification/ overexpression of YAP (KYSE170) demonstrated that knockdown of YAP reduced survivin transcription but did not affect cIAP1 expression (supplementary Figure S4A is available at Carcinogenesis Online), suggesting that survivin but not cIAP1 is a possible direct target mediating YAP function at least in ESCC cells, possibly due to cellular context. Our double-knockdown experiments in ESCC cells (supplementary Figure S4 is available at Carcinogenesis Online) and a previous study with in mouse models (12) demonstrate that YAP and cIAP1 cooperatively contribute to tumorigenesis and progression possibly by mediating different pathways. Although diap1, a Drosophila homologue of cIAP1, is known to be a direct target for yki and contributes to tissue overgrowth, our results in ESCC cells indicate that cIAP1 is co-overexpressed with YAP through co-amplification within the same amplicon and not through direct targeting of YAP at least in esophageal carcinogenesis.
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